They tested their nanoparticle construct in vitro in p53 S241F ES-2 ovarian cancer cells and in vivo in an orthotopically implanted p53 Y220C patient-derived xenograft breast cancer model [76]. This evidence concerns the gene TP53 and ovarian cancer.